Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Dan O who wrote (8201)	1/6/1999 1:27:00 AM
From: aknahow	Respond to of 17367

The middle column of the WSJ, is always a slice of life thing. Typical topic, How a one eyed frog, in the land of oz got squashed to death, before he could become king, by a tin can rolling down a yellow brick road. Meaning it's a waste of time, but here's this retired guy in love with biotecks over the long term . He became a millionaire, investing in biotechs, because he started with more and then he even had less. But in Aug, he invested about $170,000 more in about 8 biotechs one of which was XOMA . This was the 2nd. mention and the first was simply a WSJ mention of XOMA as one of several that had disappointed investors. This is done from memory, and I do not consider the details as important. Though I don't like the middle column story most people do. It is probably one of the first things many WSJ readers read. Caution, stocks go up and down for lots of reasons. Three things happened today but perhaps the rise was related to none of them. I just think that of the 3 that happened the WSJ may have been more important than M. Murphy since a Murphy or MacCamant plug for XOMA is nothing new. I say that understanding they reach people that have never heard the story before each time they repeat it.